Purpose We aimed at designing and developing a novel bombesin analogue, DOTA-PEG4-BN(7-14) (DOTA-PESIN), with the goal of labelling it with 67/68 Ga and 177 Lu for diagnosis and radionuclide therapy of prostate and other human cancers overexpressing bombesin receptors. Methods The 8-amino acid peptide bombesin (7-14) was coupled to the macrocyclic chelator DOTA via the spacer 15-amino-4,7,10,13-tetraoxapentadecanoic acid (PEG 4 ). The conjugate was complexed with Ga(III) and Lu(III) salts. The GRP receptor affinity and the bombesin receptor subtype profile were determined in human tumour specimens expressing the three bombesin receptor subtypes. Internalisation and efflux studies were performed with the human GRP receptor cell line PC-3. Xenografted nude mice were used for biodistribution.
Introduction
Radionuclides coupled to receptor-specific peptides are currently under investigation in clinical trials involving different tumours [1] . They specifically localise receptors overexpressed on the plasma membrane and then internalise into cells [2] [3] [4] . The prototypes of these peptides are analogues of somatostatin [5] .
In designing radiometal-based radiopeptides for cancer diagnosis and treatment, important factors to consider are half-life, mode of decay, cost and availability of the radionuclide. In diagnostic imaging [6] , 99m Tc, 123 I, 67 Ga and 111 In are used for SPECT and 18 F, 11 C, 64 Cu and 68 
Ga for positron emission tomography (PET).
177 Lu-labelled peptides have become attractive in targeted radiotherapy of small tumours or metastases owing to their excellent radiophysical properties and commercial availability of the radionuclide [5, 7, 8] . 68 Ga, on the other hand, is a promising metallic positron emitter (t 1/2 =68 min, 89%, E β + max =1.90 MeV) for regular use in PET imaging because of its production from a 68 Ga/ 68 Ge generator, which allows independence from an on-site cyclotron and offers almost unlimited availability if two or three of these generators are used concomitantly as elution is possible every 3 h [9, 10] . To develop a ligand for the labelling with these two radionuclides would therefore seem promising.
In the field of radiolabelled peptides, bombesin (BN) analogues have become a promising class of ligands as gastrin-releasing peptide (GRP) receptors, a subtype of BN receptors, were found to be overexpressed on primary prostatic invasive carcinoma (and their invaded lymph nodes), breast tumours and gastrointestinal stromal tumours [11] . Up to now, many types of radiolabelled BN analogues have been designed to target GRP receptor-expressing tumours [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . In particular, Van de Wiele et al. reported on a first study of prostate (n=4) and breast cancer (n=6) patients [13, 25] . Their results showed that 99m Tc-RP527 visualised four of six breast and one of four prostate carcinomas. This radiopeptide showed inferior properties to many other radiopeptides in the PC-3 tumour-bearing nude mouse model [26] . As 99m Tc (6) (7) (8) (9) (10) (11) (12) (13) (14) ) has shown higher affinity to the GRP receptor and a higher tumour accumulation in PC-3 tumour-bearing mice [27] than 99m Tc-RP527, it may be a superior candidate for studying in patients.
We have recently developed DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-and DTPA-modified (pan)BN radioligands having high affinity to all three human BN receptors [i.e. neuromedin B receptor (NMB-R), GRP-R and BN receptor subtype-3 (BB3)] [17] . Preliminary results in clinical studies of two of these radiopeptides have shown occasional uptake in the pancreas and relatively fast washout from lesions when labelled with 111 In. The fast washout may be due to a low metabolic stability of these radiopeptides. Therefore, we set up a programme to synthesise BN-based radiopeptides with improved metabolic stability, an optimised tumour-to-kidney ratio and lack of affinity to BB3. From a series of peptides evaluated, DOTA-PEG 4 -BN(7-14) (DOTA-PESIN) looked particularly promising in our preclinical studies.
Here we present data on the synthesis and labelling of this peptide with the positron emitter 68 Ga, the γ-and Auger electron emitter 67 Ga and the β(γ)-emitter
177
Lu. In addition, we studied the receptor subtype affinity profile and the in vivo biodistribution of radiolabelled DOTA-PESIN with regard to BN receptor subtypes. PET imaging and scintigraphy were also performed.
Materials and methods
All chemicals were obtained from commercial sources and used without further purification. Rink amide 4-methylbenzhydrylalanine (MBHA) resin and all Fmoc-protected amino acids are commercially available from NovaBiochem (Laeufelfingen, Switzerland). [
67 Ga]Cl 3 was purchased from Mallinckrodt Medical (Petten, the Netherlands) and [ 177 Lu]Cl 3 from IDB (Petten, the Netherlands). Fmoc-15-amino-4,7,10,13-tetraoxapentadecanoic acid (Fmoc-PEG 4 -OH) was obtained from Quanta BioDesign (Powell, Ohio, USA) and 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid-t-butyl ester)-10-acetic acid [DOTA-tris( t Bu ester)] from Macrocyclics (Dallas, Texas, USA). Electrospray ionisation mass spectroscopy was carried out with a Finnigan SSQ 7,000 spectrometer (Bremen, Germany) and MALDI-MS measurement on a Voyager sSTR equipped with an Nd:YAG laser (Applied Biosystems, Framingham, USA). Ten milligrams of 3,5-dimethoxy-4-hydroxycinnamic acid were dissolved in 0.05% TFA of acetonitrile/ water (1:1) and used as matrix. Analytical high-performance liquid chromatography (HPLC) was performed on a Hewlett Packard 1050 HPLC system with a multiwavelength detector and a flow-through Berthold LB 506 Cl γ-detector (Regensdorf, Switzerland) using a Macherey-Nagel Nucleosil 120 C 18 column (Oensingen, Switzerland) (eluents: A=0.1% TFA in water and B=acetonitrile; gradient: 0-20 min, 80%-50% A; 21-24 min, 100% B; 24-25 min, 80% A). Preparative HPLC was performed on a Metrohm HPLC system LC-CaDI 22-14 (Herisau, Switzerland) with a Macherey-Nagel VP 250/21 Nucleosil 100-5 C 18 column (eluents: A= 0.1% TFA in water and B=acetonitrile; gradient: 0-10 min, 70%-52% A; 11-14 min, 100% B; 14-15 min, 70% A). Quantitative γ-counting was performed on a COBRA 5003 γ-system well counter from Packard Instruments (Meriden, CT, USA). Solid phase peptide synthesis was performed on a semiautomatic peptide synthesiser commercially available from Rink Combichem Technologies (Bubendorf, Switzerland). The cell culture medium was Dulbecco's minimal essential medium (DMEM) with 10% or 1% foetal calf serum (FCS) from BioConcept (Allschwil, Switzerland). PET imaging was performed on a Siemens ECAT EXACT HR + scanner (Siemens/CTI, Knoxville, TN, USA), and scintigraphic imaging was carried out on a PRISM 2000 XP camera (Philips, the Netherlands). 68 Ga was obtained from a 68 Ge/ 68 Ga generator which consists of a column containing a self-made phenolic ion exchanger loaded with 68 Ge and coupled in series with a small anion exchanger column (AG 1×8 Cl-1, mesh 200-400; Bio-Rad, Munich, Germany) to concentrate 68 Ga during elution [28] .
Synthesis
DOTA-PESIN was synthesised on solid support as described previously [17] . In brief, the peptide was assembled on a Rink amide MBHA resin according to classical Fmoc chemistry on a semi-automatic peptide synthesiser. Ga in 0.2 ml/ 0.5 mol/l HCl was evaporated to dryness and redissolved in 0.2 ml acetate buffer (pH 4.8, 0.1 mol/l). After addition of 5 μl of a 1 mmol/l aqueous DOTA-PESIN solution, the mixture was kept for 10 min at 90°C. The uncomplexed 68 Ga was separated by adsorption onto a SepPak C 18 cartridge that was equilibrated with 0.1 mol/l acetate buffer (pH 6.2), whereas [ 68 Ga]-DOTA-PESIN was eluted with 1.5 ml ethanol. After evaporation of the organic solvent, the radiotracer was redissolved in 0.01 mol/l phosphate-buffered saline (pH 7.4) containing 0.5 mg/ml human serum albumin. The preparations were checked for bound and free 68 Ga by paper chromatography using Whatman No.1 and methanol/0.01 mol/l acetate buffer (pH 6.2) at a ratio of 55:45. 68 Ge contamination of the [ The binding affinity profile for the three BN receptor subtypes was determined as described in detail previously [11, 30] Internalisation and efflux studies
Internalisation and externalisation experiments were performed in six-well plates as described previously [17] .
Briefly, approximately 3 kBq (0.25 pmol) of [ 177 Lu/ 67 Ga]-DOTA-PESIN was added to PC-3 cell-containing incubation medium (0.5-1×10 6 cells per well) and incubated at 37°C in a 5% CO 2 environment at different time points (0.5, 1, 2, 4 and 6 h). A large excess of [Ga III ]-DOTA-PESIN (0.4 μmol/l, 150 μl) was used to determine non-specific internalisation. At each time point, the internalisation was stopped by removal of the medium followed by washing the cells with ice-cold solution composed of 0.9% NaCl/0.01 mol/l Na 2 HPO 4 /0.01 mol/l KH 2 PO 4 (pH 7.2). Cells were then treated (twice) with glycine buffer (0.05 mol/l glycine solution, pH adjusted to 2.8 with 1 mol/l HCl) for 5 min to distinguish between cell surface-bound (acid buffer removable) and internalised (acid-resistant) radioligand. Finally, cells were detached from the plates by incubation with 1 mol/l NaOH for 10 min at 37°C, and the radioactivity was measured in a gamma counter. The percentage of added activity per million cells (% of total) was calculated for internalisation at each time point.
For externalisation studies, PC-3 cells were allowed to internalise [ 177 Lu/ 67 Ga]-DOTA-PESIN for 2 h; they were then exposed to an acid wash, as described in the internalisation experiments, to dissociate the cell surface-bound radioligand. Then 1 ml of culture medium (1% FCS) was added to each well, the cells were incubated at 37°C in a 5% CO 2 environment and the externalisation of the cellincorporated radioactivity was studied at different times. The culture medium was collected and measured for radioactivity. The percentage of total internalised radiotracer was calculated for efflux.
Biodistribution experiments in PC-3 tumour-bearing nude mice After a slight anaesthesia with isoflurane in an air/oxygen mixture, athymic nude female mice (Harlan, the Netherlands) were implanted subcutaneously on the right flank with about 10 million PC-3 tumour cells, which were freshly expanded in 100 μl sterilised PBS solution.
Seven to ten days after inoculation the tumours weighed 60-130 mg and the mice were injected via the tail vein with 10 pmol radiolabelled peptide (about 0.12 MBq [
67 Ga]-DOTA-PESIN), diluted in 0.9% NaCl (0.1% BSA, pH 7.4, total injected volume 100 μl). For the determination of nonspecific uptake in the tumour and receptor-positive organs, a group of four animals was injected with a mixture of 10 All animal experiments were performed in compliance with the Swiss regulations for animal treatment (Bundesamt für Veterinärwesen, approval no. 789), or with the German laws for the protection of animals.
Statistical analysis
Data are expressed as mean ± SD, which were calculated on Microsoft Excel. Student's t test (Origin 6, Microcal Software, Inc., Northampton, MA) was used to determine statistical significance at the 95% confidence level with p<0.05 being considered significantly different.
Results

Synthesis and radiolabelling
DOTA-PESIN (Fig. 1) Receptor binding affinity and profile ]BN(6-14) as radioligand, the binding studies showed good binding affinities to NMB-R and GRP-R, and no affinity to BB3-R.
Internalisation and efflux studies
Internalisation of both radiopeptides was followed for 6 h. Both 177 Lu-and 67 Ga-labelled DOTA-PESIN showed specific and time-dependent cell uptake, reaching 39.1± 1.1% and 43.7±1.8% of the total amount added to the medium, respectively, after 6 h of incubation at 37°C (Fig. 2) . Within the first 2 h of incubation [
177 Lu]-DOTA-PESIN internalised somewhat faster than [
67 Ga]-DOTA-PESIN but after 4 h there was no statistical difference. The efflux kinetics (Fig. 3) showed a cellular retention of 52.5± 1.6% of the total internalised activity 20 h after start of efflux for both radiopeptides.
Animal biodistribution studies
Biodistribution studies using the 67 Ga/ 177 Lu-labelled peptides were performed with athymic nude female mice bearing the PC-3 human prostate tumour; the results are presented in Tables 2 and 3 67 Ga]-DOTA-PESIN resulted in a >94% reduction of uptake in the tumour and also in a reduction of uptake in other GRP-R-positive organs, e.g. >95% in the pancreas and 97% in the pituitary, 83-85% in the adrenals, spleen and bowel, and 78% in the stomach, showing specific receptormediated uptake in these tissues. The injection of the blocking dose had no significant influence on the uptake in other non-target organs whereas it led to a somewhat decreased kidney uptake. Co-injection of lysine did not reduce the kidney uptake, and the ratio between tumour and kidney remained almost unchanged. The impact of the blocking dose on biodistribution of [
177 Lu]-DOTA-PESIN can be seen from the scans shown in Fig. 6 .
Due to the rapid clearance from the body, high tumourto-background ratios were found (Table 3 ). These ratios increased with time. For instance, the ratios of Lu-labelled (○) DOTA-PESIN from PC-3 cells. Cells were allowed to internalise for 2 h. Data are from two independent experiments with triplicates in each experiment and are expressed as % specifically externalised of total activity internalised added to the medium 48 h and 2.43±0.12 %IA/g at 72 h. In the pancreas, [ 177 Lu]-DOTA-PESIN was released faster than the 67 Galabelled peptide. In addition, the release of [
177 Lu]-DOTA-PESIN from the pancreas and kidneys was faster than from the tumour, leading to an increasing tumour-to-organ ratio with time.
PET imaging
Iteratively reconstructed PET images of PC-3 tumour xenografts with [ 68 Ga]-DOTA-PESIN (1.94 MBq, 15 pmol) were performed at 1 h post injection (Fig. 5) . The PC-3 tumour was located in the thoracic wall, and was perceptible with clear contrast from the adjacent background in the transaxial slices. Coronal slices distinctly show the tumour and kidneys. Sagittal slices demonstrate that [ 68 Ga]-DOTA-PESIN accumulates predominantly in the PC-3 tumour, pancreas and kidneys. The results of direct tissue counting and of PET imaging were consistent.
Scintigraphy Figure 6 shows the scintigraphic imaging of PC-3 tumour xenografts with [ 177 Lu]-DOTA-PESIN (left: unblocked; right: blocked with 50 μg [Ga III ]-DOTA-PESIN). Imaging was performed at 4, 24, 48 and 72 h after injection. In the blocked mouse the tumour could not be visualised and only the kidneys were visible, whereas the PC-3 tumour of the non-blocked mouse was visualised with clear contrast from the adjacent background at all time points. Prominent uptake was also observed in the pancreas and kidneys. The imaging kinetics showed that [
177 Lu]-DOTA-PESIN was preferably retained in the tumour rather than in the pancreas and kidneys. These imaging results are consistent with biodistribution data (Fig. 4) .
Discussion
We report on the development of a radiopeptide which can be used in SPECT ( 67 Ga), PET ( 68 Ga) and targeted radionuclide therapy ( 177 Lu) of BN receptor-positive tumours such as prostate and breast cancer or gastrointestinal stromal tumours. As part of a small library of peptides, which differ by the spacer between the chelate and the pharmacophoric peptide, DOTA-PEG 4 -BN (7) (8) (9) (10) (11) (12) (13) (14) appeared to have promising properties in terms of a relatively high tumour-to-kidney and tumour-to-liver ratio. Therefore we decided to study this peptide in depth after labelling with 67 Ga, 68 Ga and 177 Lu with the aim of introducing these radiopeptides into the clinic. DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) was chosen as chelator since it forms M 3+ complexes with high in vitro and in vivo stability [32] . PEG 4 (15-amino-4,7,10,13-tetraoxapentadecanoic acid) was chosen as spacer and pharmacokinetic modifier. Very long PEG-based spacers (>3,000 D) coupled to peptides or antibodies appear to decrease the binding affinity of these biomolecules to their receptors and to lower the rate of internalisation significantly, as shown by Rogers et al. using a [
64 Cu]-DOTA-PEG-BN (7-14) derivative [33] . Smaller versions do not seem to have a sufficient influence on the pharmacokinetics and hydrophilicity [31, 33] .
The presented peptide was synthesised on solid phase with an overall yield of >45%. 68 Ga labelling was straight- (6) (7) (8) (9) (10) (11) (12) (13) (14) showed that both metallopeptides have good to moderate affinity to the GRP and the NMB receptor and no affinity to the BB3 receptor. The affinities are about ten times lower than those of truncated BN (7) (8) (9) (10) (11) (12) (13) (14) and intact BN derivatives coupled to bifunctional tetra-amines, which show IC 50 values between 0.2 and 2 nmol/l to the GRP receptor and, with one exception, also to the NMB receptor. values below 1 nmol/l [19] . There was no significant difference in affinity between the peptides metallated with Ga 3+ or Lu 3+ . This is in contrast to DOTA-octreotide derivatives; these conjugates show a distinctly improved binding affinity when labelled with radiogallium [32, 34] .
The rate of internalisation into PC-3 cells was similar for the two radiopeptides and somewhat more efficient than the internalisation of the panbombesin ligands studied previously in the same assay and under the same conditions [17] . This similarity does not reflect the distinct difference in binding affinity. The high rate of internalisation of the two radiopeptides indicates that they are agonists. with a somewhat different rate (t 1/2 ( 67 Ga)=16.5±2.4 h; t 1/2 ( 177 Lu)=12.8±1.4 h) [31] . A prolonged intracellular retention is of importance if long-lived radionuclides are to be used in therapy studies.
After administration of [ 67 Ga/ 177 Lu]-DOTA-PESIN, clearance from the circulation was fast and whole body clearance proceeded via the urinary system, unlike the positively charged 99m Tc-N 4 -labelled BN analogues, which are partly excreted via the hepatobiliary tract [19, 27] . Clearance from GRP receptor-negative tissues was also rapid except from the kidneys.
Initially, tumour uptake was very high (14.8% IA/g at 1 h), approaching the uptake of the best radiopeptides studied so far in the PC-3 tumour model [27] . This new radiopeptide has a high tumour-to-liver ratio which may make it even somewhat superior to the best 99m Tc-labelled peptides [19] . The uptake in tumour, pancreas, intestine and pituitary was specific and receptor mediated, as shown by the co-injection of cold peptide, indicating that these organs are also GRP receptor positive. Unlike others [16, 35, 36] we also found a decrease in the kidney uptake when a peptide-blocking dose was administered, whereas a substantial reduction in kidney uptake upon blocking was also shown recently by use of an 18 F-labelled Lys 3 -BN derivative [37] . The fast background clearance of the radiogallium peptide renders [
68 Ga]-DOTA-PESIN an ideal radiotracer for PET imaging. The relatively fast initial washout from the tumour may be explained by radioligand not being internalised and being metabolised during its presence in the tumour compartment.
The structural entities which confer the suitable pharmacokinetic properties to this molecule most likely reside in the PEG 4 spacer. Preliminary data using shorter and longer spacers indicate that PEG 4 has an optimal length. The lack of affinity to the BB3 receptor may be advantageous as this orphan receptor is expressed in the human pancreas.
Conclusion
Despite the relatively low binding affinity of [Lu III , Ga III ]-DOTA-PESIN the corresponding radiopeptides show suitable pharmacokinetics in the PC-3 tumour-bearing mouse model, with high tumour uptake and relatively slow washout from the tumour. The radiopeptides show superior tumour-to-liver and suitable tumour-to-kidney ratios in comparison with our earlier published radiopeptides and even with the best 99m Tc-labelled BN analogues. This renders the new peptides suitable for clinical studies.
